Orbital is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement.

In April 2023, Orbital announced the successful closing of a $270 million Series A financing.